Addison Advisors LLC Has $28,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Addison Advisors LLC cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 85.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,111 shares of the company’s stock after selling 12,497 shares during the period. Addison Advisors LLC’s holdings in Takeda Pharmaceutical were worth $28,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Cromwell Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $61,000. Ieq Capital LLC raised its holdings in shares of Takeda Pharmaceutical by 86.9% in the fourth quarter. Ieq Capital LLC now owns 21,241 shares of the company’s stock valued at $281,000 after purchasing an additional 9,874 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock valued at $67,000 after purchasing an additional 4,260 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Takeda Pharmaceutical by 50.7% in the fourth quarter. Allworth Financial LP now owns 9,582 shares of the company’s stock valued at $124,000 after purchasing an additional 3,222 shares during the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Takeda Pharmaceutical by 1.6% in the fourth quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock valued at $29,266,000 after purchasing an additional 35,192 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $14.36 on Wednesday. The company has a market cap of $45.68 billion, a price-to-earnings ratio of 35.89, a PEG ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The company’s fifty day simple moving average is $13.33 and its 200 day simple moving average is $13.88. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.